São Paulo - Delayed Quote BRL

Dr. Reddy's Laboratories Limited (R1DY34.SA)

13.63

0.00

(0.00%)

At close: January 27 at 1:23:42 PM GMT-3

RDY Q3 Earnings Match Estimates, Generics Revenues Rise Y/Y, Stock Down

Dr. Reddy's stock falls on Q3 fiscal 2025 results, wherein earnings match estimates but revenues beat the same.

Zacks 5 days ago

RDY
Dr Reddy's Laboratories Ltd (RDY) Q3 2025 Earnings Call Highlights: Record Revenue Growth ...

Dr Reddy's Laboratories Ltd (RDY) reports a robust 16% YoY revenue growth, driven by strategic product launches and market expansions, despite facing price erosion and compliance challenges.

GuruFocus.com 6 days ago

RDY
Indian drugmaker Dr Reddy's shares slide after Q3 profit miss

The generic drugmaker was the top loser on the Nifty Pharma index and the benchmark Nifty 50 index. "The drop in shares comes as market sees near-term concerns over the company's muted U.S. sales," said Sumit Gupta, analyst at Centrum Broking. Indian generic drugmakers are struggling with slower sales in the United States, delayed approvals for new drug applications and lower pricing amid stiff competition.

Reuters 6 days ago

RDY
Dr Reddy's Laboratories Q3 Earnings: Double-Digit Growth Aided By Newly Acquired Nicotine Replacement Business

On Thursday, Dr. Reddy's Laboratories Ltd (NYSE:RDY) stock is trading lower after the company released third-quarter 2025 earnings. The pharma company clocked a net income of $165 million, marginally up from $161 million a year ago. Revenue increased from $843 million to $977 million — almost a 16% jump. The growth was largely driven by revenues from the recently acquired Nicotine Replacement Therapy (NRT) portfolio, as well as revenues from India and Emerging Markets. Last year, Haleon plc (NYS

Benzinga 6 days ago

RDY
Dr. Reddy’s Q3 & 9MFY25 Financial Results

HYDERABAD, India, January 23, 2025--Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter and nine months ended December 31, 2024.

Business Wire 6 days ago

RDY
Indian drugmaker Dr Reddy's says it is 'optimistic' about Trump administration

BENGALURU/HYDERABAD (Reuters) -Indian generic drugmaker Dr Reddy's Laboratories on Thursday said it was optimistic about the Donald Trump administration, as it believes the country would have an edge amid tensions between the United States and China. "I believe that the type of products that we bring in and the positioning of India is favorable," CEO Erez Israeli said in a press call, adding that the company's drugs in the U.S. market are cheaper than the current alternatives. Earlier in the day, the generic drugmaker reported consolidated net profit of 14.14 billion rupees ($163.7 million) for the quarter ended Dec. 31, missing analysts' estimate of 14.89 billion rupees as per data compiled by LSEG.

Reuters 6 days ago

RDY
Dr. Reddy’s Laboratories Allocates Equity Shares to Employees

Dr Reddy’s Laboratories ( (RDY) ) has provided an update. Dr. Reddy’s Laboratories has approved the allotment of 13,080 equity shares to employees under its Employees Stock Options Scheme, 2002, as part of its commitment to rewarding and retaining talent. This move reflects the company’s strategic approach to employee compensation and its continuous efforts to align employee interests with its business objectives, potentially enhancing stakeholder value. More about Dr Reddy’s Laboratories Dr. Re

TipRanks last month

RDY
Dr. Reddy’s Boosts Workforce with Equity Allotment

Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s Laboratories has announced the allotment of 26,150 equity shares to employees who exercised their stock options under the company’s 2002 Employee Stock Options Scheme. This move reflects the company’s ongoing commitment to rewarding its workforce and could potentially influence investor sentiment positively. As these shares are fully paid and identical to existing shares, it ensures seamless integration into the current market str

TipRanks last month

RDY
Dr. Reddy’s Launches Innovative Cancer Drug in India

Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s Laboratories has launched Toripalimab in India, marking it as the first immuno-oncology drug approved for nasopharyngeal carcinoma (NPC) in the country. This launch positions India as the third nation globally to access this innovative treatment, following China and the U.S. Toripalimab has demonstrated a 48% reduction in disease progression risk when combined with standard chemotherapy, addressing a significant need for advanced

TipRanks last month

RDY
Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma

HYDERABAD, India, November 28, 2024--Dr. Reddy’s Laboratories Ltd. announced the launch of Toripalimab in India.

Business Wire 2 months ago

RDY
Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market

HYDERABAD, India, November 26, 2024--Dr. Reddy's Laboratories, Inc. and Senores Pharmaceuticals, Inc. today announced the launch of Ivermectin Tablets USP, 3 mg in the U.S. market.

Business Wire 2 months ago

RDY
Dr. Reddy’s Gains Strong Rating Amid Robust Growth

Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s Laboratories has received an ‘IND AA+/Stable’ rating from India Ratings & Research for its bank facilities, reflecting a solid financial position and continued growth in the US generic market. The company’s robust performance is driven by a diverse product mix, strategic launches, and improved operating efficiencies, despite challenges such as regulatory concerns and divestment impacts in India. Investors may find Dr. Reddy’s stro

TipRanks 2 months ago

RDY
Dr. Reddy's Q2 Earnings Miss Estimates, Global Generics Revenues Grow

RDY misses on earnings but beats on revenues in the fiscal second quarter. The bottom line suffers due to a one-time acquisition cost and impairment charge on non-current assets.

Zacks 2 months ago

RDY
Dr Reddy's Laboratories Ltd (RDY) (HY 2025) Earnings Call Highlights: Strong Revenue Growth and ...

Dr Reddy's Laboratories Ltd (RDY) reports robust revenue growth and strategic advancements, despite challenges in North America and increased SG&A expenses.

GuruFocus.com 2 months ago

RDY
Dr. Reddy’s Q2 & H1FY25 Financial Results

HYDERABAD, India, November 05, 2024--Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter and half year ended September 30, 2024.

Business Wire 2 months ago

RDY
India's Dr Reddy's Q2 profit drops on acquisition cost, impairment charge

HYDERABAD/BENGALURU (Reuters) -Indian generic drugmaker Dr Reddy's Laboratories' second-quarter profit was hit by one-time charges related to its joint venture with Nestle India and Nicotinell acquisition, the company said on Tuesday. The company also reported an impairment charge due to supply chain constraints in U.S. affecting a particular generic medical product. Analysts on average had estimated a profit of 14.01 billion rupees, as per data compiled by LSEG.

Reuters 2 months ago

RDY
Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year

HYDERABAD, India, October 25, 2024--Dr. Reddy’s has been ranked among the top employers according to the 2024 Top Biotech and Pharma Employers Survey conducted by Science.

Business Wire 3 months ago

RDY
Dr. Reddy’s Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month

PRINCETON, N.J., October 14, 2024--Dr. Reddy’s launches comprehensive menopause support program and training for employees during menopause awareness month.

Business Wire 3 months ago

RDY
Dr. Reddy’s Subsidiary Triumphs in CAR-T Cell Therapy Trial

Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s subsidiary Aurigene Oncology Limited reports positive Phase 1 results for India’s first novel CAR-T cell therapy trial in multiple myeloma patients. The therapy, Ribrecabtagene autoleucel, showed a 100% clinical response rate without any high-grade safety concerns, paving the way for the Phase 2 trial with regulatory approval. These findings could mark a significant advancement in treatment options for Indian myeloma patients. For

TipRanks 3 months ago

RDY
Dr. Reddy’s Laboratories Limited (RDY): Among the Best Indian Stocks for the Next 10 Years

We recently compiled a list of the 10 Best Indian Stocks for Next 10 Years. In this article, we are going to take a look at where Dr. Reddy’s Laboratories Limited (RDY) stands against the other Indian stocks. India’s strong growth trajectory remains a compelling narrative on the back of remarkable advancements throughout sectors, placing the […]

Insider Monkey 3 months ago

RDY

Performance Overview

Return	R1DY34.SA	S&P BSE SENSEX
YTD	-16.07%	-2.20%
1-Year	+20.64%	+6.37%
3-Year	+27.31%	+33.79%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Dr. Reddy's Laboratories Limited (R1DY34.SA)

RDY Q3 Earnings Match Estimates, Generics Revenues Rise Y/Y, Stock Down

Dr Reddy's Laboratories Ltd (RDY) Q3 2025 Earnings Call Highlights: Record Revenue Growth ...

Indian drugmaker Dr Reddy's shares slide after Q3 profit miss

Dr Reddy's Laboratories Q3 Earnings: Double-Digit Growth Aided By Newly Acquired Nicotine Replacement Business

Dr. Reddy’s Q3 & 9MFY25 Financial Results

Indian drugmaker Dr Reddy's says it is 'optimistic' about Trump administration

Dr. Reddy’s Laboratories Allocates Equity Shares to Employees

Dr. Reddy’s Boosts Workforce with Equity Allotment

Dr. Reddy’s Launches Innovative Cancer Drug in India

Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market

Dr. Reddy’s Gains Strong Rating Amid Robust Growth

Dr. Reddy's Q2 Earnings Miss Estimates, Global Generics Revenues Grow

Dr Reddy's Laboratories Ltd (RDY) (HY 2025) Earnings Call Highlights: Strong Revenue Growth and ...

Dr. Reddy’s Q2 & H1FY25 Financial Results

India's Dr Reddy's Q2 profit drops on acquisition cost, impairment charge

Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year

Dr. Reddy’s Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month

Dr. Reddy’s Subsidiary Triumphs in CAR-T Cell Therapy Trial

Dr. Reddy’s Laboratories Limited (RDY): Among the Best Indian Stocks for the Next 10 Years

Performance Overview